SecBot SecBot
PRESS-RELEASE ·Filed Jul 28, 2026

LAB

Standard BioTools Inc.
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

The $30M cash infusion and HSR clearance significantly reduce deal risk and improve the pro forma balance sheet ahead of the Treeline merger. Monitor the stockholder vote and any competing bids; the merger is on track for year-end 2026 close.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.7947
T+0 close · Jul 28, 2026 · via day close
Latest settled
−18.21%
T+60 · $0.6500
Vs SPY
−22.56%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 28 $0.7947entry
  2. T+1 · 4mo ago +9.97%α +11.50% · $0.8739
  3. T+5 · 4mo ago +9.00%α +6.73% · $0.8662
  4. T+20 · 3mo ago −18.21%α −21.59% · $0.6500
  5. T+60 · 27d ago −18.21%α −22.56% · $0.6500
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Standard BioTools announced the sale of its Mass Cytometry business to Multiplex Bio for up to $10M, received ~$30M from Illumina to buy out earnout/royalty obligations, and secured early HSR termination for its pending merger with Treeline Biosciences. These actions strengthen the balance sheet, reduce contingent liabilities, and de-risk the Treeline merger, which is expected to close by year-end 2026.

Key Financial Metrics

Deal Value
$10.0M

Key Facts

  • Sale of Mass Cytometry business to Multiplex Bio for up to $10 million (seller's note + milestone payment)
  • Received approximately $30 million from Illumina to buy out 2026 earnout and all future royalty payments related to the SomaLogic acquisition
  • U.S. FTC granted early termination of HSR waiting period for the Treeline merger
  • Treeline merger and Mass Cytometry sale expected to close by end of 2026, subject to stockholder approval and customary conditions
  • Standard BioTools will provide Multiplex Bio with a working capital loan of up to $10 million at closing

Financial Impact

~$30M cash received from Illumina buyout; up to $10M from Mass Cytometry sale (seller's note + milestone); up to $10M working capital loan to Multiplex Bio

cash positioncontingent liabilitiesdeal value

Risk Factors

  • Stockholder approval required for both the Mass Cytometry sale and the Treeline merger
  • Customary closing conditions may delay or prevent the transactions
  • Potential for competing acquisition proposals or termination of the Treeline merger

Market Snapshot

Exchange
Nasdaq
Sector
Laboratory Analytical Instruments
Analyst Consensus
67% bullish (6 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3334170

Track record

23 reports on LAB

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +17.95% at T+20 after the Feb 24, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 425 Neutral 4/10 Entry price pending
  2. Nov 16, 2026today 8-K Neutral 3/10 Entry price pending
  3. Nov 3, 202613d ago 425 Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 4/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  5. Nov 3, 202613d ago Press Release Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  6. Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $0.6400 to $0.6056 Now $0.6200 −3.12% ▼ −5.38% −4.85% vs SPY
  7. Oct 21, 202626d ago S-4/A Bearish 7/10 Entry $0.6500 to $0.6400 Now $0.6200 +4.62% ▲ +1.54% +0.36% vs SPY
  8. Oct 9, 20265w ago S-4/A Neutral 6/10 Entry $0.6578 to $0.6589 Now $0.6200 −5.75% ▲ +0.17% +0.18% vs SPY
  9. Oct 5, 20266w ago 425 Neutral 5/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
  10. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (9h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 28, 2026